

J.P. Morgan Healthcare Conference Presentation

January 12, 2023

Forward Looking Statements

This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex[®] Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause act ual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any "phase" of clinical trials. We also cannot be sure of the clinical outcome for efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.



Anavex Overview

NASDAQ AVXL	HEADQUARTERS
TEAMMATES	cash & cash equivalents ¹
CNS DISORDERS MARKET OPPORTUNITY ² \$232.2B	PATIENTS WITH CNS DISORDERS WORLDWIDE ³ 67.5M+

World-wide patent protection for all listed product candidates



Precision Therapeutics

Every person is unique: aspire to develop therapeutic treatments tailored to suit each individual's unique medical condition



Anavex is dedicated to therapeutic discovery and development of novel small molecule treatments for central nervous system (CNS) diseases including Alzheimer's Disease, Parkinson's Disease Dementia and Rett Syndrome, among other rare diseases



Company's precision platform, SIGMACEPTOR[™], has enabled the development of drugs that unlock the body's own defenses to treat, and in some cases potentially reverse, CNS conditions



Aiming to bring the Company's treatments to market to benefit patients across the globe

〇〇 Community-based 同 Insights

Value and rely on communitybased partnerships to inform our decision making and strategy development processes

Scientific

Therapeutic development model is designed to identify and innovate novel therapeutic solutions that are rooted in science

○ Inclusion & ○ Equitable Access

Global institutional need for change: committed to serving the diverse human population and to implementing inclusive and equitably accessible therapeutic programs



- 1. As of September 30, 2022.
- 2. Source: https://www.alliedmarketresearch.com/central-nervous-disorders-therapeutics-market-A13
- 3. Sources available on slide 20 of this presentation.



Precision medicine platform and novel central nervous system mechanism improve chance of clinical success



Several promising differentiated therapeutics for challenging CNS diseases with unmet medical needs



Achieved multiple successful clinical milestones and progressing from a research focus to a commercial stage company to bring therapies to patients around the world



Positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



Anavex Precision Platform Enables a Novel Approach

Targeting CNS conditions with genomic precision and restoring neuronal homeostasis via SIGMAR1 activation

Proprietary SIGMACEPTOR[™] Discovery Platform produces small molecule therapeutic candidates for targeting the SIGMAR1 mRNA biomarker

Age-related Changes

Chronic CNS pathologies, including progressive chronic Alzheimer's, cause exhaustion of the body's own SIGMAR1 activators, impairing the body's response to chronic cellular stress

Progressive CNS Pathology (e.g., AD, PD)

Impaired body-own compensatory SIGMAR1 response to chronic cellular stress

ANAVEX[®]2-73

ANAVEX[®]2-73 (blarcamesine) re-establishes the body's own SIGMAR1 response and restores SIGMAR1 levels Beneficial therapeutic effect for patients



ANAVEX[®]2-73 Establishes SIGMAR1 mRNA Biomarker of Efficacy in Alzheimer's, Parkinson's and Rett Syndrome

ANAVEX[®]2-73 positive response in functional

outcome correlate with SIGMAR1 mRNA levels

ANAVEX[®]2-73 improves functional (ADCS-ADL*) outcome in Alzheimer's disease patients correlating with SIGMAR1 mRNA levels

SIGMAR1 mRNA EXPRESSION (TPM) 50 p=0.015 Clinical ANAVEX[®]2-73 p-value of Mannimprovements Treatment VIA SIGMAR1 40 Whitney U test measured by: mRNA Expression All n=20 patients in study (dose range 30 10mg-50mg). Change of ADCS-ADL* from baseline to week 57 ... IN PATIENTS WITH PARKINSON'S DISEASE with available genomic 20 data CDR system CoA (p = 0.029) MDS-UPDRS Part III (p = 0.024) CDR system PoA (p = 0.015) MDS-UPDRS Total (p = 0.038) 10 ... IN PATIENTS WITH RETT SYNDROME 0 RSBQ (p = 0.035) CGI-I (p = 0.029) No improvement Improved outcome (Negative change) (Positive change)


Confirmed with independent SIGMAR1 variant analysis

Source: Hampel H et al. Alzheimer's Dement. 2020;00:1–14; *Alzheimer's Disease Cooperative Study Activities of Daily Living 23-item scale (ADCS-ADL)

1. Results from ANAVEX[®]2-73-PDD-001 Parkinson's disease dementia study

Precision Platform Shows Promise for Superior Care

Anavex is positioned to target significant unmet medical needs across CNS conditions




 1 K. Ruscher, T. Wieloch, The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration, Journal of Pharmacological Sciences, Volume 127, Issue 1, 2015, Pages 30-35, ISSN 1347-8613, <u>https://doi.org/10.1016/j.jphs.2014.11.011</u>.
 2 J. Narwan et al., Pages 17 20, ISSN 1247-8613.

 L. Nguyen et al., Role of sigma-1 receptors in neurodegenerative diseases, Journal of Pharmacological Sciences, Volume 127, Issue 1, 2015, Pages 17-29, ISSN 1347-8613, https://doi.org/10.1016/j.jphs.2014.12.005.



Precision Medicine Increases Likelihood of Clinical Success Through Efficacy of Drug Targeting



Biomarkers increase probability of success



Thomas DW et al. Clinical Development Success Rates 2011-2020. BIO | QLS Advisors | Informa UK Ltd 2021



Precision medicine platform and novel central nervous system mechanism improve chance of clinical success



Several promising differentiated therapeutics for challenging CNS diseases with unmet medical needs



Achieved multiple successful clinical milestones and progressing from a research focus to a commercial stage company to bring therapies to patients around the world



Positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



Transformative Precision Platform Drives Impactful Therapies

Novel approach and transformative technology will likely continue to produce a variety of CNS treatments

Proprietary SIGMACEPTOR™ Discovery Platform

SIGMAR1 mRNA biomarker with genomic precision

Targeted treatment

Late-Stage Pipeline has Achieved **Clinical Milestones for Ongoing Development**

ANAVEX[®]2-73 (blarcamesine)

ANAVEX®3-71 (AF710B)

- Alzheimer's Disease
- Parkinson's Disease Dementia
- Parkinson's Disease
- **Rett Syndrome**

- Schizophrenia
- Frontotemporal Dementia (FTD)
- Alzheimer's Disease

Promising Early-Stage Pipeline

ANAVEX[®]2-73 (blarcamesine)

- Fragile X Syndrome
- Infantile Spasms
- Angelman Syndrome
- Undisclosed **Rare Disease**

ANAVEX®1-41

- Depression
- Stroke
- Neurodegenerative Diseases

ANAVEX®1066

- Visceral Pain
- Acute & Neuropathic Pain

Manavex

10

Treating Alzheimer's Disease (AD)

Progressive, neurological disease and the most common cause of dementia¹


- Progressive development; slowly destroys memory and thinking skills
- Impacts nearly every aspect of a person's life as it progresses: short-term memory loss and confusion, difficulty learning new things, delusions and disorientation, inability to recognize common things
- Current annual cost of dementia is estimated at \$1T, a figure set to double by 2030



~35M people worldwide living with AD²

~6.5M people in the U.S. living with AD²

Manavex[®]



2. Sources available on slide 20 of this presentation.


Treating Parkinson's Disease (PD) & Parkinson's Disease Dementia (PDD)

Motor disorder in which patients suffer from tremors in their extremities and head, stiff limbs and inability to relax muscles during episodes

- Up to 80% of those with Parkinson's disease (PD) eventually experience Parkinson's disease dementia
- Progressive development; can cause numerous cognitive and behavioral deficits
- Parkinson's disease is a fairly common neurological disorder in older adults, estimated to affect nearly 2% of those over the age of 65

STAGE 1

STAGE 2



>1% of the world population has PD

STAGE 3

(Planned Trials)

(Planned Trials)

>1.5M Americans affected by PD today



Source: Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3. PMID: 28257128; PMCID: PMC5643027; www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia

CANDIDATE

ANAVEX[®]2-73

(blarcamesine)

ANAVFX[®]2-73

(blarcamesine)

PARKINSON'S

PARKINSON'S

DISEASE

DISEASE DEMENTIA

Treating Rett Syndrome

Neuro-developmental disease in girls with both movement impairment and cognitive impairment¹

- Cognitive and motor delays begin to manifest along with slower head growth following relatively normal infancy (i.e., around 1.5 to 3 years of age, loss of spoken language and hand skills begin to develop)
- Associated with four key symptoms: loss of expressive language, loss of fine motor skills, • impaired ability to walk and repetitive hand movement
- Second most common cause of severe intellectual disability in females •

TAGE 1 ST	TAGE 2	STAGE 3
	A	EXCELLENCE NAVEX®2-73-RS-003 (ongoing trial)
U.S. ANAV	EX®2-73-RS-001	
0.0.740700		
	Δ.Ν	AVATAR AVATAR VAVEX®2-73-RS-002
	U.S. ANAV	U.S. ANAVEX®2-73-RS-001



~350,000 patients diagnosed with Rett

Syndrome worldwide¹

~11,000 patients diagnosed with Rett Syndrome in the U.S.²



2. Sources available on slide 20 of this presentation.

Source: https://www.rettsyndrome.org/about-rett-syndrome.



Precision medicine platform and novel central nervous system mechanism improve chance of clinical success



Several promising differentiated therapeutics for challenging CNS diseases with unmet medical needs



Achieved multiple successful clinical milestones and progressing from a research focus to a commercial stage company to bring therapies to patients around the world



Positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



Multiple Clinical Milestones Achieved and Promising Ongoing Development Driving Progress towards Commercialization

CANDIDATE		PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
ANAVEX®2-73		ALZHEIMER'S DISEASE			AD ANAVEX®2-73-AD-004
blarcamesine	FOR PARKINSON'S RESEARCH	PARKINSON'S DISEASE DEMENTIA		ANAVEX®2-73-PDD-001	
	THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH	PARKINSON'S DISEASE			
	International Rett Syndrome Foundation	*RETT SYNDROME		EXC	CELLENCE ANAVEX [®] 2-73-RS-003 (ongoing trial)
	International Rett Syndrome Foundation	*RETT SYNDROME		AVATARANAVEX®2-73-RS-001	Fast Track, Rare Pediatric, Orphan Drug (U.S./EU)
	International Rett Syndrome Foundation	*RETT SYNDROME			AVATARANAVEX®2-73-RS-002
	- Culturion	*INFANTILE SPASMS			
		*FRAGILE X			
	FAST Protection for Application	ANGELMAN'S			
		UNDISCLOSED RARE DISEASE			
ANAVEX®3-71		SCHIZOPHRENIA	ANAVEX®3-71-001		
AF710B		*FRONTOTEMPORAL DEMENTIA (FTD)	ANAVEX®3-71-001		
		ALZHEIMER'S DISEASE	ANAVEX®3-71-001		
ANAVEX®1-41		DEPRESSION			
		STROKE			
		NEURODEGENERATIVE DISEASES			Legend
ANAVEX®1066		VISCERAL PAIN			Solid bar = completed trials ¹ Dashed lines = planned trials
		ACUTE & NEUROPATHIC PAIN			

* Orphan Drug Designation by FDA

1. EXCELLENCE: Ongoing trial

Mana

ANAVEX[®]2-73 AD-004 Phase 2b/3 Alzheimer's Disease Trial

Global, multicenter, randomized, double-blind, placebo-controlled, parallel group, 48-week trial evaluating ANAVEX[®]2-73 (blarcamesine) once daily oral

Solid trial design produced reliable and meaningful data

N=509

Early AD patient population

- Confirmed AD pathology / amyloid pathophysiology (CSF/amyloid PET)
- Patients aged 60 to 85 years
- MMSE score 20-28



Primary Endpoints

- ADAS-Cog¹
- ADCS-ADL²

Key Secondary Endpoint

• CDR-SB³

Pre-specified Analyses

• Genetic variants SIGMAR1 (rs1800866) exclusion on treatment effect

Other Analyses

- Structural and functional MRI
- Biomarkers: Abeta₄₀/Abeta₄₂, T-tau, P-tau, NFL, YKL-40, neurogranin, BACE1, DNA and RNA sequencing
- 1. AD Assessment Scale-Cognitive subscale. ADAS-Cog is the most common cognitive assessment instrument used in AD clinical trials all over the world.
- 2. AD Cooperative Study-Activities of Daily Living Scale. ADCS-ADL is the most common functional assessment instrument used in AD clinical trials all over the world.

RANDOMIZATION 1:1:1

3. Clinical Dementia Rating-Sum of Boxes.




ANAVEX[®]2-73 (blarcamesine) Meets Co-Primary and Key Secondary Endpoints for Patients with Early Alzheimer's Disease

- ANAVE X[®]2-73 (blarcamesine) treatment slowed decline of cognition and function in patients with early Alzheimer's disease over 48 weeks
- Patients treated with ANAVEX[®]2-73 (blarcamesine) were 84% more likely to improve cognitively compared to placebo, by ADAS-Cog score threshold change of -0.5 points or better [Odds Ratio = 1.84 (p = 0.015)]
- At clinically significant levels of improvement in function (ADCS-ADL score threshold change of +3.5 points or better), ANAVEX[®]2-73 (blarcamesine) treatment was 167% more likely to improve function compared to placebo [Odds Ratio = 2.67 (p = 0.0255)]
- Compared to placebo, ANAVEX[®]2-73 (blarcamesine) reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by the CDR-SB
- ANAVE X[®] 2-73 (blarcamesine) was generally safe and well tolerated

Next Steps

- Publish full analyses, including MRI data, prespecified biomarkers of response as well as Whole Exome Sequencing DNA data and full mRNA exome expression data collection data on biomarkers of neurodegeneration in a peer-reviewed medical journal
- Continue open-label extension study ATTENTION-AD to follow participants over 96 weeks
- Meet with regulatory authorities to discuss data with aim to bring this therapy to patients in Europe, Asia-Pacific, and the U.S.

Odds Ratio of ADAS-Cog meaningful improvement in cognition at threshold of -0.5 points or less (90% Cl)




Odds Ratio of ADCS-ADL meaningful improvement in function at threshold of +3.5 points or higher (90% Cl)





Key Endpoint CDR-SB blarcamesine vs Placebo at 48 Weeks

Change of -0.42 points, P=0.040; 27% slowing at 48 Weeks



Note: Based on intention-to-treat analysis population; CDR-SB, Clinical Dementia Rating-Sum-of-Boxes; SE, standard error.

1. Lecanemab CDR-SB-0.451 difference compared to placebo at 72 weeks; Source: https://www.eisai.com/ir/library/presentations/pdf/e4523_221130.pdf



Blarcamesine at Week 48 has **faster response** than Leqembi (Lecanemab) at Week 72¹

Blarcamesine attains similar response **24 weeks earlier** despite more advanced patients

Blarcamesine **orally once daily** versus challenges of biologic mAb-based intravenous drug

Manavex

18



Precision medicine platform and novel central nervous system mechanism improve chance of clinical success



Several promising differentiated therapeutics for challenging CNS diseases with unmet medical needs



Achieved multiple successful clinical milestones and progressing from a research focus to a commercial stage company to bring therapies to patients around the world



Positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



More than 67.5M Patients with CNS Diseases Globally

U.S. AND GLOBAL PATIENT NUMBERS

INDICATION	USA	EUROPE	ASIA	GLOBAL
Alzheimer's Disease (AD) ^{1,2}	~6,500,000	~7,800,000	~23,000,000	~35,000,000
Parkinson's Disease (PD) ^{3,4}	~1,000,000	~1,400,000	~3,000,000	~10,000,000
Frontotemporal Dementia (FTD) ⁵	~60,000	~65,000	~500,000	~800,000
Schizophrenia ^{6,7*}	~1,500,000	~3,000,000	~6,000,000	~20,000,000
Rett Syndrome (RTT) ^{8*}	~11,000	~13,000	~37,000	~350,000
Fragile X Syndrome (FXS) ^{9,10*}	~62,500	~150,000	~900,000	~1,400,000

1. Alzheimer's Association. 2022 Alzheimer's Disease Facts and Figures. Alzheimers Dement 2022;18

2. Dementia in the Asia Pacific Region. Alzheimer's Disease International 2014; 10

3. Marras C et al 2018. npj Parkinson's Disease volume 4, Article number: 21

4. GBD 2016 Parkinson's Disease Collaborators. The Lancet 2018 Volume 17, Issue 11, P3939-953

5. Knopman & Roberts 2011. J Mol Neurosci 2011;45(3):330-335

6. National Alliance on Mental Illness, 2019

7. Fasseh et al., 2018. Eur J Public Health. 2018 Dec 1;28(6):1043-1049

8. Rettsyndrome.org, 2016

9. National Fragile X Foundation, 2022

10. Hunter et al., 2014. Am J Med Genet A. 2014 Jul; 164A(7): 1648-5



20

* Patient estimates derived from the published prevalence estimate range for the regional population

Positioned to Capitalize on a Significant and Growing Market Opportunity to Treat CNS Diseases


Worldwide dementia cases projected to grow to over 130M by 2050

>\$20T Cumulative costs of Alzheimer's and dementia care from 2015 to 2050 1 in 3

Medicare dollars will be spent on people living with Alzheimer's and other dementias in 2050

>11M The number of Americans providing unpaid care for people with Alzheimer's or other dementias

Targeting these markets using a differentiated and transformative precision platform



Source: World Alzheimer's Report

Secured Worldwide Commercial Rights to Capitalize on Valuable Pipeline and Global Opportunity

Aiming to bring lead therapies to patients in Europe, Asia-Pacific, and the U.S. following regulatory discussion



Foundation for More Cost Effective & Safer Treatments for CNS Conditions

Oral Solid ANAVEX[®]2-73 (blarcamesine)

- Alzheimer's Disease
- Parkinson's Disease Dementia
- Parkinson's Disease

Oral Liq	luid
ANAVEX®	2-73 (blarcamesine)

- Rett Syndrome
- Fragile X Syndrome
- Infantile Spasms
- Angelman Syndrome

Oral Solid ANAVEX®3-71 (AF710B)

- Schizophrenia
- Frontotemporal Dementia (FTD)
- Alzheimer's Disease



~60%

of established small-molecule drug products available commercially are administered orally¹

~90% of the global market share of all pharmaceutical formulations for humans are oral¹

~84% of the best-selling pharmaceutical products are orally administered¹

Wanavex

Orally-administered candidates offer immense potential for clinical benefit relative to costly and logistically challenging biologic mAb-based drugs, which also often present additional safety challenges

23



Precision medicine platform and novel central nervous system mechanism improve chance of clinical success



Several promising differentiated therapeutics for challenging CNS diseases with unmet medical needs



Achieved multiple successful clinical milestones and progressing from a research focus to a commercial stage company to bring therapies to patients around the world

Positioned for future expansion with worldwide commercial rights and strong IP foundation

Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



Anavex's Strong Financial Profile Supports Operations and Clinical Programs are Funded for 4 Years

Disciplined approach to operational expenditures
24.2M Fiscal year 2022 cash utilization
Sufficient cash runway
Est. Years of Runway

operations and non-dilutive cash sources





Values-Driven Team with Track Record and Expertise Capable of Advancing Anavex's Cutting-Edge Precision Platform

Christopher U. Missling, PhD

President & CEO

20+ years of experience in the healthcare industry within large pharmaceutical companies, the biotech industry and investment banking

CURIS IMMUNOGEN #Aventis

Edward R. Hammond, MD, MPH, PhD

Chief Medical Officer

15+ years of exceptional expertise in clinical drug development, including the approval of medicines and beyond



Walter E. Kaufmann, MD

Chief Scientific Officer

20+ years of experience in clinical studies with focus on developing novel therapies for genetic disorders associated with intellectual disability



Emmanuel O. Fadiran, RPh, PhD

SVP of Regulatory Affairs

26+ years of experience in government service



Adebayo Laniyonu, PhD

SVP of Nonclinical Development

24+ years of experience with US Food and Drug Administration (FDA)



Daniel Klamer, PhD

VP of Business Development & Scientific Strategy

15+ years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the USA







26

Purpose-Built Scientific Advisory Board

Dag Aarsland, MD, PhD Andrew Cole, MD **Corinne Lasmezas, PhD Diverse skillset tailored ZING'S** HARVARD MEDICAL SCHOOL to Anavex's portfolio College **Scripps Research** \propto LONDŐN **Daniel Weintraub, MD Jacqueline French, MD Jeffrey Cummings, MD** School of Medicine 🌾 NYU CNS Drug development Cleveland Clinic Trial design and analysis Norman Relkin, MD, PhD Ottavio Arancio, MD, PhD Paul Aisen, MD Academic and research USC University of Southern Californi COLUMBIA UNIVERSITY 1 Weill Cornell Medicine MEDICAL CENTER Southern California thought leadership Clinical expertise in ၂၅ **Tangui Maurice**, PhD **Timo Grimmer, MD** treating CNS diseases UNIVERSITÉ DE MONTPELLIER Technische Universität München

27

\$232.2B CNS DISORDERS MARKET OPPORTUNITY¹

67.5M+ PATIENTS WITH CNS DISORDERS WORLDWIDE²

- Source: <u>https://www.alliedmarketresearch.com/central-nervousdisorders-therapeutics-market-A13121</u>
- 2. Sources available on slide 20 of this presentation.



Precision Medicine Platform and Novel Central Nervous System Mechanism Improve Chance of Clinical Success

Targeting CNS conditions with genomic precision and restoring neuronal homeostasis via SIGMAR1 activation



Several promising Differentiated Therapeutics for Challenging CNS Diseases with Unmet Medical Needs

Novel approach and transformative technology will likely continue to produce a variety of CNS treatments

Achieved multiple successful Clinical Milestones and Progressing from a Research focus to a Commercial stage Company to bring Therapies to Patients around the World

ANAVEX[®]2-73 (blarcamesine) met co-primary and key secondary endpoints for patients with early Alzheimer's disease



Positioned for Future Expansion with Worldwide Commercial Rights and Strong IP Foundation

Positioned to capitalize on significant market opportunities around the globe with orallyadministered candidates



Sufficient Cash Runway Due to Disciplined Operations and Non-Dilutive Cash Sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and the Australian government

Estimated that operations and clinical programs are funded for 4 years





Contact Us

Corporate Office

Anavex Life Sciences Corp. 630 5th Avenue, 20th floor New York, NY 10111

1-844-689-3939

Shareholder & Media Relations

ir@anavex.com www.anavex.com

NASDAQ: AVXL